Financing the Next Verifiable Milestone: A Deep-Tech Diligence and Learning Protocol

1. Write the claim register before arranging a demonstration

The deal lead records what the company must accomplish for its investment thesis to work. Each entry names a claim, its unit of measurement, the existing evidence, its source and the condition under which the claim would be considered unsupported. Separate a verified observation from an estimate supplied by management and from an investor's inference. Preserve the date and version of every important document.

For example, a claim that a robotics component improves throughput must identify the existing process, operating environment, period of observation, downtime treatment and quality requirements. A laboratory cycle-time result does not answer all of those questions. The register should show which additional evidence is needed before the improvement can be assumed in a commercial model.

The founder-team record names the capabilities required to deliver the next milestone and the people responsible for them. Check relevant work and references with appropriate permission. The venture-capital survey [1] motivates taking team assessment seriously, but its findings do not validate a prestige score. Distinguish a founder's scientific contribution from their availability, managerial responsibilities and ability to recruit complementary expertise.

2. Commission technically independent challenge

Choose a reviewer with expertise in the specific technology and disclose conflicts, compensation and relationships to the company or sourcing network. Relevant independence is more than a different email address. A reviewer whose future business depends on the sponsor may need a second reviewer or a clearly recorded limitation.

Give the reviewer the raw evidence permitted for review, not just the investor presentation. Ask what the demonstration establishes, what it leaves unresolved and which alternative explanation could produce the same result. Preserve negative findings and requests for additional evidence. If access to essential data is unavailable, describe the resulting limit explicitly.

The network study [6] is compatible with networks providing useful information; it is not a reason to dispense with challenge. The objective is to use relationships to obtain better evidence while retaining the ability to disagree with the people who supplied the opportunity.

3. Design one discriminating milestone

For a hypothetical industrial component, specify a controlled comparison with the customer's current process, using a defined mix of tasks and a pre-agreed measurement window. Outcomes might include completed units meeting quality standards, downtime, operator intervention and total operating cost. The customer and technical reviewer should determine meaningful acceptance limits before observing the results. No numeric performance threshold is proposed here because the application determines what matters.

Record who conducts the test, who observes it, how equipment and software versions are preserved, how missing observations are handled and what would trigger a repeat. Avoid selecting only favorable tasks after seeing the data. Keep a log of deviations and explain whether they affect interpretation.

Howell's grant research [2] motivates the distinction between financing a prototype and merely purchasing a reputational signal. This protocol's test design is an editorial extension, not a tested consequence of that study. The proposed investment packet should show which uncertainty the funding addresses and what decisions follow success, partial success and failure. A failed test can be valuable information without being a successful investment.

4. Assess integration and the operating system around the technology

Prepare a dependency map covering software, components, specialist labor, supply chain, facilities and customer integration. Identify single points of failure and alternatives that could be used in practice. Component readiness, system readiness and production repeatability should have distinct evidence entries. A demonstration assembled by its inventors may not establish that a customer can operate and maintain the product.

GAO's 2020 guide [4] provides a reference for structured technology-readiness assessment, not certification of this protocol. Adapt the questions to the venture rather than assign an authoritative-looking readiness number without supporting evidence. Record operating conditions and integration assumptions so future reviewers can understand what a test actually demonstrated.

For applications involving sensitive data or consequential automation, identify the deployment environment, access boundaries, failure response and responsible operator. These requirements affect feasibility and costs. They should appear in the commercial model rather than being treated as work someone will resolve after investment.

5. Resolve commercialization rights through the actual institution

The appropriate legal specialist reviews the executed license or option, the assets it covers, the permitted uses and material obligations. If the company is still negotiating, record that status. Confirm the relevant institution's process directly and distinguish the inventor's personal role from the institution's authority over the technology.

Stanford's published process [3] illustrates why a development plan, license scope, milestones and conflicts need attention. It does not establish the terms of another institution's agreement. This protocol does not provide legal conclusions about patent validity or freedom to operate. Those questions require the relevant documents and qualified analysis.

Record what happens to essential rights if a founder leaves, a milestone is missed, the business changes direction or financing is delayed. Identify which questions have documentary answers and which remain subject to negotiation. An unresolved right essential to the product is not a minor diligence item that can be offset by a strong technical score.

6. Test customer economics and the investor's own security

Interview an authorized customer representative about the actual buying process: problem, budget, competing alternatives, integration costs, evidence required and decision timing. Distinguish an introduction, a letter of interest, a paid evaluation and an enforceable purchase commitment. Avoid treating a prestigious institution's willingness to meet as evidence that it will buy.

Build scenarios for the specific security being acquired. Include dilution assumptions, relevant preferences, fees, conversion terms and restrictions where applicable. Show proceeds under several explicitly hypothetical outcomes. A qualified professional should verify contractual interpretation. Gornall and Strebulaev [5] demonstrate why share-class terms matter; their historical modeled valuation gap is not a percentage to deduct mechanically from a present offer.

Use a plain-language reconciliation between the company headline valuation, the assumptions about the investor's ownership and the possible cash proceeds. If that reconciliation cannot be produced, a claim that an investment has multiplied in value is incomplete. For unrealized holdings, preserve uncertainty rather than convert a financing announcement into a realized return.

7. Make the milestone a decision, not a ritual

The committee's authorization names the current amount, the next evidence requirement, the person who can accept that evidence and any conditions for further commitment. A follow-on reserve is a planning assumption unless a binding obligation exists; show the distinction. Identify whether the family can tolerate losing the committed amount while meeting its other obligations.

Define three outcomes before funding: proceed when specified evidence supports the next step; revise when a particular uncertainty remains addressable within a justified budget; stop when a critical assumption fails or the necessary rights and resources cannot be obtained. Preserve the possibility of stopping without requiring reviewers to prove that the science has no value anywhere.

If a milestone changes, retain the prior version and explain the new evidence that warrants revision. Moving a threshold merely because it was missed destroys the value of pre-specification. Conversely, rigidly preserving an obsolete test can also impair judgment. The record should make the distinction assessable by someone who was not present in the room.

8. Evaluate usefulness and disclose failure

Before adopting the protocol across live transactions, test it on anonymized cases with known evidence gaps. Compare identification of material problems, false alarms, review time and agreement across qualified assessors. Random assignment and blinded scoring can strengthen that initial evaluation when feasible. Do not use fabricated cases to claim observed investment success.

For live use, maintain a prospective register of evidence requests, decisions, costs and later milestone outcomes, including deferred and declined opportunities where information is available. Separate operational learning from a formal human-participant research project; obtain necessary approvals and permissions before collecting confidential participant information for publication.

The protocol fails if it produces attractive documents that do not change the handling of missing evidence, or if its costs outweigh its decision value. It also fails if a prominent sponsor can silently override the conditions applied to other opportunities. Reporting such failures is part of evaluating the design. No effect on returns, technical success or institutional reputation is claimed without an appropriate study.

References and evidence access

[1] Gompers, Paul A.; Gornall, Will; Kaplan, Steven N.; Strebulaev, Ilya A. (2020). How do venture capitalists make decisions? Journal of Financial Economics, 135(1), 169–190. DOI: 10.1016/j.jfineco.2019.06.011. Evidence inspected: institutional working-paper abstract, Chicago Booth; final publication metadata checked separately. https://www.chicagobooth.edu/research/fama-miller/finance-research/working-papers/2016/how-do-venture-capitalists-make-decisions

[2] Howell, Sabrina T. (2017). Financing Innovation: Evidence from R&D Grants. American Economic Review, 107(4), 1136–1164. DOI: 10.1257/aer.20150808. Evidence inspected: American Economic Association article record and abstract. https://www.aeaweb.org/articles?id=10.1257/aer.20150808

[3] Stanford University Office of Technology Licensing (undated; accessed 21 October 2026). Licensing Process. Institutional guidance, not an empirical investment study. https://otl.stanford.edu/industry/licensing-process

[4] U.S. Government Accountability Office (2020). Technology Readiness Assessment Guide: Best Practices for Evaluating the Readiness of Technology for Use in Acquisition Programs and Projects. GAO-20-48G, reissued 11 February 2020. Evidence inspected: official report record and highlights. https://www.gao.gov/products/gao-20-48g

[5] Gornall, Will; Strebulaev, Ilya A. (2020; online 2019). Squaring venture capital valuations with reality. Journal of Financial Economics, 135(1), 120–143. DOI: 10.1016/j.jfineco.2018.04.015. Evidence inspected: Stanford GSB Preserve publication record and abstract. https://gsbpreserve.stanford.edu/view/43588/squaring-venture-capital-valuations-with-reality

[6] Hochberg, Yael V.; Ljungqvist, Alexander; Lu, Yang (2007). Whom You Know Matters: Venture Capital Networks and Investment Performance. Journal of Finance, 62(1), 251–301. DOI: 10.1111/j.1540-6261.2007.01207.x. Evidence inspected: NYU institutional abstract of the 20 April 2005 working-paper version; version distinction retained. https://archive.nyu.edu/handle/2451/26413

Editorial contribution and provenance

Paired conceptual article: https://journal.research.university/journals/family-office-private-wealth/articles/napa-2026-science-to-enterprise. This proposed protocol has not been tested.

Prepared by the Family Office Private Wealth Journal editorial research desk at Dr. Freedom Cheteni’s direction, with AI assistance for literature discovery, critical synthesis and drafting. Published as original editorial analysis by The Research University. No independent peer-review decision, primary-study result, institutional endorsement or new DOI is claimed.

Conference context: attendee-supplied transcript installments received 21 October 2026 from the Opal Group Family Office & Private Wealth Management Forum West. The installments overlap and contain uncertain speaker turns, incomplete names and transcription errors. They motivate questions, not verified performance observations. No recording or reliable timestamps were supplied. No speaker is represented as an author or endorser, and no audio excerpt is attached.

Evidence access is specified in each reference. Citations to non-CC scholarship are links and bounded summaries, not full-text republication. The new editorial license does not extend to cited works, speaker remarks or recordings. Examples and evaluation protocols are explicitly hypothetical or proposed. This publication provides general scholarly and educational analysis, not individualized investment, legal or tax advice.

Implementation record

Open the cited sources

1. [1] Gompers, Paul A.; Gornall, Will; Kaplan, Steven N.; Strebulaev, Ilya A. (2020). How do venture capitalists make decisions? Journal of Financial Economics, 135(1), 169–190. DOI: 10.1016/j.jfineco.2019.06.011. Evidence inspected: institutional working-paper abstract, Chicago Booth; final publication metadata checked separately. ↗
2. [2] Howell, Sabrina T. (2017). Financing Innovation: Evidence from R&D Grants. American Economic Review, 107(4), 1136–1164. DOI: 10.1257/aer.20150808. Evidence inspected: American Economic Association article record and abstract. ↗
3. [3] Stanford University Office of Technology Licensing (undated; accessed 21 October 2026). Licensing Process. Institutional guidance, not an empirical investment study. ↗
4. [4] U.S. Government Accountability Office (2020). Technology Readiness Assessment Guide: Best Practices for Evaluating the Readiness of Technology for Use in Acquisition Programs and Projects. GAO-20-48G, reissued 11 February 2020. Evidence inspected: official report record and highlights. ↗
5. [5] Gornall, Will; Strebulaev, Ilya A. (2020; online 2019). Squaring venture capital valuations with reality. Journal of Financial Economics, 135(1), 120–143. DOI: 10.1016/j.jfineco.2018.04.015. Evidence inspected: Stanford GSB Preserve publication record and abstract. ↗
6. [6] Hochberg, Yael V.; Ljungqvist, Alexander; Lu, Yang (2007). Whom You Know Matters: Venture Capital Networks and Investment Performance. Journal of Finance, 62(1), 251–301. DOI: 10.1111/j.1540-6261.2007.01207.x. Evidence inspected: NYU institutional abstract of the 20 April 2005 working-paper version; version distinction retained. ↗